Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | angiotensin II receptor, type 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | pyroglutamylated rfamide peptide receptor | angiotensin II receptor, type 1 | 359 aa | 403 aa | 19.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0131 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0065 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0131 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0131 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0116 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0131 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0131 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0131 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0081 | 0.2407 | 0.2407 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0116 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0131 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0131 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0131 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0131 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0131 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0131 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0131 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0131 | 1 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0131 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0131 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0066 | 0.0151 | 0.0151 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0131 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0065 | 0 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0131 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0131 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0131 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0131 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0081 | 0.2407 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0131 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.06 uM | Tested for inhibition of Angiotensin II receptor, type 1 in the absence of bovine serum albumin (BSA) | ChEMBL. | No reference |
IC50 (binding) | = 0.06 uM | Tested for inhibition of Angiotensin II receptor, type 1 in the absence of bovine serum albumin (BSA) | ChEMBL. | No reference |
IC50 (functional) | = 0.068 uM | Tested for inhibition of Angiotensin II-induced pressor response in rabbit aorta | ChEMBL. | No reference |
Inhibition (functional) | = 10 % | Tested for inhibition of Angiotensin II-induced pressor response in pithed rat model after 10 mg/kg peroral administration | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.